Tau-directed mAb receives US FDA fast track designation
The US Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb).
The therapy from Johnson & Johnson is being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase IIb AuTonomy study.
It has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid (CSF) from treated AD patients, and in blocking the development and spread of tau aggregates in non-clinical models of disease.
“As the average age of the global population increases, the number of people impacted by this debilitating progressive disease continues to rise. Alzheimer’s disease places a substantial emotional and financial burden on patients and their loved ones and has a significant economic and societal impact,” said Bill Martin, Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine.
“Posdinemab has the potential to slow the spread of tau pathology in the brain – which may slow cognitive decline. The FDA’s Fast Track designation reflects the urgent unmet need for new treatment options for the millions living with AD.”
Posdinemab is designed to bind to pathological phosphorylated tau when it is released from neurons and neutralise it before it can seed/spread to another neuron. The compound has shown promise in reducing tau seeding – the process by which toxic tau spreads through the brain – in both in vitro and in vivo non-clinical studies.
Posdinemab is the second Fast Track designation granted in 2024 for the company’s AD portfolio. J&J’s anti-tau active immunotherapy JNJ-2056 was also granted Fast Track designation in July 2024.
The Phase IIb ReTain trial will evaluate the potential of JNJ-2056 to activate the immune system to help generate antibodies against pathological phosphorylated tau, with the goal of delaying or preventing onset of symptoms, and ultimately disease progression.
Diana Spencer, Senior Digital Content Editor, DDW
